• LevelJump Healthcare Corp (JUMP) will be conducting a non-brokered private placement
  • The offering will consist of 10 million units priced at $0.15 per unit for gross proceeds of up to $1.5M
  • Each unit will consist of one common share and one common share purchase warrant
  • Purchase warrants will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20
  • Leveljump Healthcare provides radiology solutions for hospitals, emergency rooms and private clinics
  • LevelJump Healthcare Corp. (JUMP) is down 11.36 per cent, trading at C$0.195 per share at 10:30 am ET

LevelJump Healthcare Corp (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $1,500,000.

The offering will consist of 10 million units priced at $0.15 per unit.

Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 for a period of 36 months from the date of closing.

The offering is only open to residents of Canada who are accredited investors as defined under applicable securities legislation.

Net proceeds will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in early May and is conditional upon receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange.

The securities to be issued under the offering will have a hold period of four months and one day from the closing date of the offering in accordance with applicable securities laws.

Leveljump Healthcare provides radiology solutions for hospitals, emergency rooms and private clinics. 

LevelJump Healthcare Corp. (JUMP) is down 11.36 per cent, trading at C$0.195 per share at 10:30 am ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.